Assessment of Nucleotide Excision Repair XPD Polymorphisms in the Peripheral Blood of Gemcitabine/Cisplatin–Treated Advanced Non–Small-Cell Lung Cancer Patients

Only about one third of non—small-cell lung cancer (NSCLC) patients respond to cisplatin-based chemotherapy. Cisplatin DNA adducts are commonly repaired through the nucleotide excision repair pathway. The study of rare inherited disorders such as xeroderma pigmentosum and Cockayne syndrome has discl...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clinical lung cancer Ročník 4; číslo 4; s. 237 - 241
Hlavní autoři: Camps, Carlos, Sarries, Carmen, Roig, Bárbara, Javier Sánchez, José, Queralt, Cristina, Sancho, Eva, Martinez, Natividad, Tarón, Miguel, Rosell, Rafael
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States Elsevier Inc 01.01.2003
Témata:
Chemotherapy resistance
Cockayne syndrome
DNA adducts
DNA repair
ERCC1
Transcription-coupled repair
Xeroderma pigmentosum genes
Cockayne syndrome
Chemotherapy resistance
ERCC1
DNA adducts
DNA repair
Transcription-coupled repair
Xeroderma pigmentosum genes
ISSN:1525-7304, 1938-0690
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Only about one third of non—small-cell lung cancer (NSCLC) patients respond to cisplatin-based chemotherapy. Cisplatin DNA adducts are commonly repaired through the nucleotide excision repair pathway. The study of rare inherited disorders such as xeroderma pigmentosum and Cockayne syndrome has disclosed that XP genes, including XPD, play an essential role in DNA repair, both in the global genomic repair and in the transcription-coupled repair pathways. XPD polymorphism and decreased expression of XP genes have both been linked to lower DNA repair capacity. ERCC1 overexpression has been associated with cisplatin resistance, and experimental evidence shows a close association between ERCC1 and XPD. In the present study, we have examined XPD polymorphisms at codons 751 and 312 in DNA isolated from peripheral blood in 39 patients with gemcitabine/cisplatin—treated locally advanced non-small-cell lung cancer. Although no significant correlation was observed between XPD genotype and objective response, a trend toward better response was observed in patients with XPD polymorphism at codon 312. The map of the nucleotide excision repair pathway can be used to design translational research studies to identify and validate predictive markers of response to cisplatin, and the Spanish Lung Cancer Group has recently accrued 250 gemcitabine/cisplatin—treated NSCLC patients for a prospective assessment of XPD genotype.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1525-7304
1938-0690
DOI:10.3816/CLC.2003.n.004